The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
about
Statins for the prevention of dementiaStatins for the primary prevention of cardiovascular diseaseStatins for the primary prevention of cardiovascular diseaseStatins for the prevention of dementiaGenome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsInflammation and infection in clinical strokeNon-homologous end-joining pathway associated with occurrence of myocardial infarction: gene set analysis of genome-wide association study data.Is the adiposity-associated FTO gene variant related to all-cause mortality independent of adiposity? Meta-analysis of data from 169,551 Caucasian adultsSubclinical thyroid dysfunction and cognitive decline in old ageAre markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly.Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).Annotation of loci from genome-wide association studies using tissue-specific quantitative interaction proteomics.Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses.Is hypercholesterolemia a risk factor and should it be treated in the elderly?Elderly patients at risk for coronary heart disease or stroke: selecting an ideal product for lipid lowering.Pharmacology and clinical experience with simvastatin.Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions.Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at RiskBlood pressure variability and cardiovascular risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).Interventions in the management of serum lipids for preventing stroke recurrence.Diabetes in tomorrow's world: dark clouds do have silver linings.Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)Hypolipemic agents for stroke prevention.Clinical trials update from the American Heart Association meeting: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure.Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and MortalityCovariate selection in high-dimensional propensity score analyses of treatment effects in small samples.Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocNon-response to (statin) therapy: the importance of distinguishing non-responders from non-adherers in pharmacogenetic studies.Hypermethylation at loci sensitive to the prenatal environment is associated with increased incidence of myocardial infarction.Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs.The Cognitive decline in Older Patients with End stage renal disease (COPE) study - rationale and design.Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium.Closing out a large clinical trial: lessons from the prospective study of pravastatin in the elderly at risk (PROSPER).Impact of gender difference on long-term outcomes of percutaneous coronary intervention for coronary artery disease in patients under statin treatment.Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study.Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.Adipocytokines and risk of stroke in older people: a nested case-control study.Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up.
P2860
Q24186591-DEC18549-6865-4279-A926-C4524A68A966Q24201513-4C538A6C-72D9-47CB-AFCF-857EC6773ED5Q24234813-0A9E2D29-CA94-4EB9-B196-4733E04B6C60Q24241335-996835B2-A2E1-4302-B433-DC35CFE21D3CQ24594382-8922D8B9-0EDF-4741-A59A-C46EF5F0126CQ24794358-70DCC24A-F5C0-4F57-9547-683844ADC2A0Q28194382-54FBF48A-29E1-46CA-B9FC-2A9BBBD9612EQ30596587-BCB2A735-526A-4CD5-82D6-305EE37C4E29Q30907369-D050E2AB-82D4-4EDD-8272-B07F04EB0256Q31114507-B3E2B6DE-3340-4F14-B110-73C8531C6A25Q33474334-E08D922C-694B-47E0-B9E1-2CE503DD7EF2Q33784552-CE9FF34E-C889-44E7-BCB0-FC1A4C6AAC00Q33826794-FA2C556A-AB97-4101-8903-E3EC8E338521Q33983329-7120B979-66C0-465F-B1F0-11E3A20A3B0BQ34041800-F58F5465-5805-4EE0-8DB1-F6E31760F76FQ34077942-EAD81EF8-5DC5-4B7C-A454-012527A39B40Q34186428-63387808-C95B-4B0A-AEBD-E9315398E77AQ34240784-8F19A4FA-EB5F-4B17-9567-A7F47D01F7D3Q34389584-613EBD64-37BD-402C-A3E1-9A37EED583EEQ34516430-C38D1BDD-FCCF-4644-9150-9F294DBE5353Q34533910-5AB2C0FA-2CDA-4CF7-855C-19B60BA21344Q34757974-EF3FAC18-50D8-4574-8843-F3C332F3AC22Q34983284-208EC51A-ABC3-4049-A9E7-4C4331BB864CQ34983980-C0738018-0BE3-46AA-9DF0-ABA15F0D2074Q35008533-B8475514-03AA-44DE-8207-32255C8EF6FCQ35057082-15DD3843-B4C7-4384-9468-A6BFF78C73D3Q35119305-D652606E-6009-4D0D-AF9A-4625357DF18BQ35133118-5B2F4DA2-0B2D-4924-84DE-C256E4BDC07EQ36188016-6D2B3234-BA11-4999-A519-08B3FF240A6BQ36688483-4A7B5E99-FCAB-4A50-BC75-BCC871AAB8F9Q36872686-43177AF6-C850-433C-A354-E677E0A940B1Q38084372-6AE76CEA-F210-4FBD-B04E-D427A0EE56CAQ38730795-709C7C37-E921-4113-BC86-0A2171F19722Q40044576-B194BF9E-C26C-4313-B585-027D256C05B3Q40373816-D5C4C00C-44C2-4A3C-A0DE-93C926FAC2D0Q40784938-80D27126-4425-4FEF-B68D-33A77EA9E8D8Q43248480-94FFFEAE-8D0C-419E-A3C6-41A16CD36D91Q44803518-866A0FAE-0978-467C-B5B9-35FF2D28703CQ46295029-AC4A7F7C-6EA1-4CF9-A1CC-68E8EC4AC82FQ46491161-1E3AE669-0E35-4FFA-880C-61BFCAE8FFBF
P2860
The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
description
im November 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 1999
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 1999
@uk
name
The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
@en
The design of a prospective study of pravastatin in the elderly at risk
@nl
type
label
The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
@en
The design of a prospective study of pravastatin in the elderly at risk
@nl
prefLabel
The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
@en
The design of a prospective study of pravastatin in the elderly at risk
@nl
P2093
P1476
The design of a prospective st ...... astatin in the Elderly at Risk
@en
P2093
A E Meinders
A M Lagaay
B J Sweeney
B M Buckley
C J Packard
E L Bollen
P304
P356
10.1016/S0002-9149(99)00533-0
P407
P50
P577
1999-11-01T00:00:00Z